Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TB155D
- Development stage
- Preclinical
- Lead developer
- Twinpig Biolab
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
TB155D is a preclinical-stage antibody-drug conjugate (ADC) being developed by TwinPigBio for the treatment of cancer. It utilizes the company's proprietary ESCLink™ platform to conjugate a Human epidermal growth factor receptor 2 (HER2)-targeting antibody with a Proteolysis-Targeting Chimera (PROTAC) payload. The therapeutic strategy involves using the antibody to selectively deliver the PROTAC into HER2-positive tumor cells, where the payload then facilitates the ubiquitination and subsequent proteasomal degradation of the cMyc (MYC) transcription factor. cMyc is a prominent oncogenic transcription factor often considered difficult to target with traditional small molecules; by combining the precision of an ADC with the degradative power of a PROTAC, TB155D aims to overcome these challenges in HER2-expressing malignancies.
Beyond the preview
Go deeper on TB155D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TB155D.